NASDAQ: BRKR · Industrial Applications and Services · 6 alerts · CIK 1109354
Share price
$60.62Close, Nov 16
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Bruker Corp filings on SEC EDGAR ↗
Bruker Corporation has appointed Dr. Eicke Latz to its Board of Directors, effective January 1, 2027, expanding the board to twelve members. Dr. Latz is a physician-scientist and biopharma entrepreneur who currently serves as the Scientific Director of the German Rheumatology Research Center. Additionally, the Board declared a quarterly cash dividend of $0.05 per share payable on January 7, 2027.
Bruker Corporation completed a reorganization of its reportable segments to streamline its organizational structure, effective July 1, 2026. The company recast its historical segment financial information for 2024, 2025, and 2026 to conform to the new structure, which now includes BSI BIOS and BSI Microbiology and Infection Diagnostics (BMID).
Bruker Corporation reported a consolidated net loss of $109.7 million for the third quarter of 2026, compared to a loss of $58.5 million in the prior year period, primarily driven by a $174.5 million goodwill impairment charge. Despite the net loss, total revenue grew slightly to $874.0 million from $860.5 million year-over-year, supported by growth in service and other revenue.
Bruker Corp reported Q3 2026 revenue of $874.0 million, a 1.6% increase year-over-year, and a non-GAAP operating margin expansion of 400 basis points to 16.3%. Despite a GAAP diluted loss per share of $(0.81) due to non-cash goodwill impairment charges, non-GAAP diluted EPS grew 24.4% to $0.56. The company reconfirmed its full-year 2026 organic revenue growth and non-GAAP EPS guidance.
Term
Q3 2026
“Bruker drives significant advances in post-genomic drug discovery and disease biology research, from proteoforms to glycobiology, and from functional protein interactions to spatial biology. These deeper insights into molecular, cell and tissue biology are foundational for successful drug development and useful AI frontier models. Together with strong growth-drivers in infectious disease diagnostics, and in deep-tech and semiconductor metrology, we are poised for growth acceleration.”
Frank H. Laukien, Bruker’s President and CEO
“In the third quarter, we achieved very significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution. Bruker’s positive booking trends continued with the fifth consecutive quarter of Bruker Scientific Instruments (BSI) book-to-bill greater than one. We see strengthening demand in most of our end markets, and in Q3 also in the US academic market. With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.”
Bruker Corporation's Board of Directors declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. The dividend is payable on December 1, 2026, to shareholders of record as of November 15, 2026.